Aurobindo Pharma (ARBP) delivered better-than-expected 4QFY24performance, led by strong traction in US generics and sustained benefitof reduced raw material prices. After two years of earnings decline, ARBPhas delivered a strong 46% YoY growth in earnings in FY24